Related to this topic: Leaflets | Support | Patient+ | UK Guidelines | Weblinks | Equipment | Books | Your Experience | Other resources | Glossaries
Print options:
Other options:
(what's this?)
PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.
Erythema Chronicum Migrans
Characteristic clinical feature of Lyme borreliosis occurring in approximately 90% patients infected with Borrelia burgdorferi transmitted to humans by the bite of ticks from the genus Ixodes.
Lyme disease occurs in temperate regions of North America, Europe, and Asia. In some countries of Europe, the incidence of Lyme disease has been estimated to be over 100 per 100,000 people a year.
The characteristic manifestation of early Lyme disease (stage 1) is erythema migrans: a circular rash at the site of the infectious tick attachment that radiates from the bite, within 2 - 40 days. It expands over a period of days to weeks in 80-90% of people with Lyme disease. Pyrexia, arthritis, musculoskeletal symptoms and local lymphadenopathy may occur.
- Starts as a red macule or papule at the site of the tick bite after a 7-10 day delay.
- Expands over days to weeks and central clearing may or may not occur.
- Associated with other symptoms of infection including fatigue, myalgia, arthralgia, headache, fever, chills, stiff neck, regional lymphadenopathy.
- Also associated with carditis, neurological disease, arthritis, acrodermatitis chronica atrophicans (swollen, bluish-red skin lesion on a distal extremity).
- Local tick bite reactions
- Tinea
- Insect bites
- Cellulitis
- Plant dermatitis.
Culture and serology if necessary for diagnosis.
Although the rash will resolve spontaneously, antibiotics hasten resolution and help prevent progression to lyme disease:
- Doxycycline is the antibacterial of choice for early Lyme disease1
- Amoxicillin, cefuroxime or azithromycin are alternatives if doxycycline is contra-indicated
- Intravenous cefotaxime, ceftriaxone, or benzylpenicillin is recommended for Lyme disease associated with moderate to severe cardiac or neurological abnormalities, late Lyme disease, and Lyme arthritis
- The duration of treatment is generally 2-4 weeks; Lyme arthritis requires longer treatment with oral antibacterial drugs
Avoid exposure to tick bites.
Document references
- British National Formulary British Medical Association and Royal Pharmaceutical Society of Great Britain. London.
Internet and further reading Acknowledgements EMIS is grateful to Dr Colin Tidy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2008.
DocID: 957
Document Version: 21
DocRef: bgp1005
Last Updated: 18 Sep 2006
Review Date: 17 Sep 2008
Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.
Related pages in Patient UK
Your Experience (^ top of page)
Please add your experience about this condition / medicineInformation leaflets related to this topic (^ top of page)
Lyme DiseasePatient Support related to this topic (^ top of page)
EuroLyme
Lyme Disease ActionMedical reference articles in PatientPlus related to this topic (^ top of page)
Lyme DiseaseUK guidelines related to this topic (^ top of page)
Guidelines on Lyme DiseaseLinks to other selected websites related to this topic (^ top of page)
Lyme DiseaseOther - Useful resources (^ top of page)
Pictures, diagrams, photos, images, etc.Evidence based medicine
Online textbooks and journals
A-Z of UK Guidelines
A-Z of Online Videos
Medline
Other good health sites
Medical equipment products related to this topic (^ top of page)

Books related to this topic (^ top of page)

Want to search some more? Use the Google Search box below to search our site.

Would you like to try our advanced on-line knowledge support system designed to provide professionals with relevant up to date information about recognition and management of disease or take the Mentor Challenge?
Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.
